Last reviewed · How we verify

Neuropharm — Portfolio Competitive Intelligence Brief

Neuropharm pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fluoxetine (prozac) Fluoxetine (prozac) marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centre Hospitalier Universitaire Dijon · 1 shared drug class
  2. Daiichi Sankyo Co., Ltd. · 1 shared drug class
  3. Fundació Sant Joan de Déu · 1 shared drug class
  4. GlaxoSmithKline · 1 shared drug class
  5. Guangdong Provincial People's Hospital · 1 shared drug class
  6. Janssen Research & Development, LLC · 1 shared drug class
  7. Johns Hopkins University · 1 shared drug class
  8. AstraZeneca · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Neuropharm:

Cite this brief

Drug Landscape (2026). Neuropharm — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neuropharm. Accessed 2026-05-14.

Related